Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
暂无分享,去创建一个
Christopher P Cannon | Marc A Pfeffer | A. Skene | M. Pfeffer | J. Rouleau | E. Braunwald | C. Cannon | D. Rader | C. McCabe | Daniel J Rader | Eugene Braunwald | Jean L Rouleau | R. Belder | S. Joyal | K. A. Hill | Carolyn H McCabe | Rene Belder | Steven V Joyal | Karen A Hill | Allan M Skene | René Belder
[1] W. O’Neill,et al. Multiple complex coronary plaques in patients with acute myocardial infarction. , 2000, The New England journal of medicine.
[2] M. Law,et al. Risk factor thresholds: their existence under scrutiny , 2002 .
[3] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[4] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[5] Allen J. Taylor,et al. Marked low‐density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis , 2004, Clinical cardiology.
[6] P. O. Bonettia,et al. Statin effects beyond lipid lowering—are they clinically relevant? , 2003 .
[7] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[8] N L Geller,et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. , 1999, Circulation.
[9] L. Wallentin,et al. Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.
[10] J M Lachin,et al. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. , 1986, Biometrics.
[11] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[12] S. Schwartz,et al. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. , 1997, The American journal of cardiology.
[13] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[14] Shah Ebrahim,et al. JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .
[15] Allen J. Taylor,et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.
[16] R. Califf,et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.
[17] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[18] M. Trip,et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.
[19] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[20] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[21] A. Skene,et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.
[22] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[23] M. Hori,et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. , 2001, Journal of the American College of Cardiology.
[24] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[25] E. Braunwald,et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.
[26] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[27] Bruce R. Brodie,et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial , 2004 .
[28] J. Larosa. New and emerging data from clinical trials of statins , 2004, Current atherosclerosis reports.
[29] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[30] J. Shepherd,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .